Aptasensors for NNK biomarkers in smoking-induced lung cancer

Abstract

The major lung carcinogen in cigarette smoke is the tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), which is metabolized to 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) and glucuronide conjugates, which are the most specific biomarkers of tobacco exposure and lung cancer risk associated with smoking. Urinary NNAL is more effective than cotinine in determining long-term exposure because it has a longer half-life of 10–18 days and is more specific. This review compares aptasensor platforms for NNK/NNAL with clinical chemistry specifications that fulfill unmet requirements for the risk stratification of lung cancer at the point of care. Pre-analytical (half-life kinetics, creatinine normalization, storage stability), aptamer selection strategies (SELEX optimization, affinity-specificity trade-offs), and four classes of aptasensors (electrochemical, optical (fluorescence/colorimetric/SERS), microfluidic/POC, and nanomaterial-amplified design) were systematically evaluated using primary studies. Analytical validation included CLSI-compliant LoD/LoQ, precision, recovery, matrix effects, interference tests, calibration traceability, and LC-MS/MS comparability. The clinical implementation parameters included reference intervals (never-smokers below 10 pg/mg creatinine), reporting standards (ng NNAL/mg creatinine), QC protocols, and decision limits for smokers. The aptasensor LoDs are in the fM-pM range with equivalent LC-MS/MS sensitivity and 15–30 min min point-of-care turnaround. It can show cross-reactivity with nicotine and cotinine. Complete CLSI validation would place aptasensors in a good position to act as substitutes for laboratory LC-MS/MS in population screening and precision prevention of lung cancer.